Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26966012 | 1.00 | MTNR1A (0.50) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL25357694 | 0.86 | KDM4E (0.45) | MTNR1AMTNR1BKDM4EALDH1A1TSHR | |
| SCHEMBL30564446 | 0.82 | CA12 (0.49) | KDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL18530389 | 0.82 | CA12 (0.49) | KDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL23497862 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1TSHRL3MBTL1NPC1 | |
| SCHEMBL23720472 | 0.78 | CA12 (0.50) | KDM4EUSP2NPC1RAB9A | |
| SCHEMBL13605765 | 0.78 | ACACB (0.49) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL15300802 | 0.78 | MTNR1A (0.73) | MTNR1AMTNR1BKDM4EALDH1A1USP2 | |
| SCHEMBL31144890 | 0.78 | HTR1B (0.44) | KDM4E | |
| SCHEMBL27142562 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025128805-A1 | A CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4540267-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119866342-A | Cyclic peptides for capturing interleukin-1 beta | 默沙东有限责任公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024215820-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023244554-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | MTNR1A 374/4885MTNR1B 304/4885KDM4E 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.